As per the report, the Size of the APAC Cell Expansion Market was valued at USD 2.49 billion in 2022 and is poised to reach USD 6.63 billion by 2027, to grow at a CAGR of 21.6% from 2022 to 2027.
Diabetes, rheumatoid arthritis, and cancer are among chronic diseases driving the global cell expansion industry forward. Furthermore, rising government spending in cell-based research and a greater focus on R&D for cell-based therapeutics are going the market forward.
The increase in focus on biopharmaceutical R&D, massive medication production, and rise in cancer prevalence are the primary driving factors for market expansion in this region. Furthermore, several local pharmaceutical and biotechnology businesses are stepping up to develop and commercialize innovative cellular therapies, boosting market growth.
Cell expansion is utilized in the creation of drugs to cure disorders. It's used to make vaccines, medications, treatments, and antibiotics. The increased prevalence of diabetes and cancer necessitates substantial study to identify new treatment options.
Emerging markets are projected to focus on the cell expansion market's growth. In recent years, India, Japan, and China have seen tremendous growth in their biotechnology and pharmaceutical industries, and this trend is likely to maintain during the forecast period.
These ethical concerns and limits on the use of cells in research severely restrict cell biology research in many nations worldwide. As a result, the cell expansion market's growth is projected to be limited.
These cells are also utilized to evaluate in vivo toxicity and pharmacokinetics in animals and humans. Furthermore, stem cell research uses human embryos for clinical purposes, which frequently results in the killing of human embryos. To keep an eye on these activities, moral authorities in Asia Pacific countries have drafted stringent restrictions.
This research report on the APAC Cell Expansion Market has been segmented and sub-segmented into the following categories.
By Cell Type:
Geographically, the China cell expansion market and India cell expansion market are expected to proliferate during the projection period, owing to increased efforts by different local pharmaceutical and biotechnology companies to develop and promote their cellular therapies. For example, in July 2019, Stempeutics Research Pvt. Ltd., an Indian business, formed an association with Kemwell Biopharma to develop Stempeucel, a stem cell-based medicine. Small and mid-sized companies are likely to benefit from such arrangements, projected to increase product sales.
The Japan cell expansion market is expected to rise at a higher CAGR due to the rising prevalence of cancer, increasing government financing, expanding research activities on stem cell therapies, and growing knowledge of sophisticated treatment approaches, growing elderly population, and the strong presence of industry companies in the region contribute to this. As a result, the demand for cell expansion platforms in this region rises.
Furthermore, ethical issues about cell biology research are constraining industry expansion. For example, Gene therapy studies, such as the recombination of genes and stem cell research therapies, need animal and human cells, necessitating the use of animals and people in cell biology research.
To regulate these activities, ethical experts in numerous nations in the Asia Pacific have drafted severe legislation. As a result, cell biology research is being restricted to a large extent in several countries across the area due to ethical concerns and prohibitions on the usage of cells for study. As a result, the Cell Expansion Market's growth is expected to be limited.
KEY MARKET PLAYERS
Some of the promising companies dominating the Asia Pacific Cell Expansion Market profiled in this report are Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT, Inc. (U.S.), and Thermo Fisher Scientific, Inc. (U.S.), Corning, Inc. (U.S.), GE Healthcare (U.K.), Lonza (Switzerland), Becton, Dickinson, and Company (U.S.), Beckman Coulter, Inc. (U.S.).,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com